Dolutegravir 50mg once daily was administered for 5 days in Period1 , and dolutegravir 50mg once daily was coadministered with either boceprevir 800mg every 8h ( Cohort1 ) or telaprevir 750mg every 8h ( Cohort2 ) for 10days in Period2 .